DTB podcast   /     Psychotropic medicines in children, warfarin vs DOAC in old age, and fezolinetant in menopause

Summary

In this podcast recorded in early July, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) continue to ignore political and sporting events and talk about the August issue of DTB. They discuss the editorial that highlights the growth in the use of psychotropic medication in children and young people and some of the challenges associated with this trend. They talk about a study that assessed the harms of changing frail older people with AF from warfarin to a DOAC. The main article is an overview of the evidence for fezolinetant for the treatment of menopausal vasomotor symptoms.

Subtitle
Duration
20:19
Publishing date
2024-07-30 00:00
Link
https://dtbbmj.podbean.com/e/dtb-august-2024/
Contributors
  BMJ Group
author  
Enclosures
https://mcdn.podbean.com/mf/web/sn625erzkk5s38zn/DTB_August_2024.mp3
audio/mpeg

Shownotes

In this podcast recorded in early July, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) continue to ignore political and sporting events and talk about the August issue of DTB. They discuss the editorial that highlights the growth in the use of psychotropic medication in children and young people and some of the challenges associated with this trend. They talk about a study that assessed the harms of changing frail older people with AF from warfarin to a DOAC. The main article is an overview of the evidence for fezolinetant for the treatment of menopausal vasomotor symptoms.